Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is a life sciences company developing pharmaceutically manufactured cannabidiol formulations (CardiolRx™ and CRD-38) as innovative therapies for heart diseases, including recurrent pericarditis (RP), acute myocarditis, and heart failure. We previously covered the company and its pipeline extensively (LINK) prior to and in preparation for the MAvERIC-Pilot trial (NCT05494788) readout […]
April 11th Biotech Update
Unfortunately, not much has changed since I noted that the sector is back in the interest rate slump. We were negative for the year and that was completely predicable once the interest rate specter raised its head once again. There is no chance that we get a sustained rally as long as we are in […]
Cardiol Therapeutics: Near-Term Pericarditis Clinical Proof-of-Concept Data Catalyst, a Turning Point for Cardiol and its Valuation
Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) is a Canadian company developing pharmaceutically manufactured prescription strength cannabidiol products (CardiolRx™ and CRD-38) as small molecule therapies for heart diseases, including pericarditis, acute myocarditis, and heart failure. CardiolRx™, its proprietary oral formulation, is currently in multiple Phase 2 clinical trials, one of which is set to read out […]
March 27th Biotech Update
Well, yesterday was a start that ended in a whimper. We have had these little starts to a recovery before, but they barely lasted more than a couple of days. I sort of wonder if we are now in a new range with $98 as the upper boundary. That would not be the worst scenario […]
Medicenna – Unlocking IL-2 and Other Cytokines’ Immunotherapy Efficacy with Optimized Selectivity, Dosing, and Safety
MDNA.TO (TSX – Canada), MDNAF (OTCQB – USA) Medicenna is a clinical-stage immunotherapy company developing novel, selective IL-2, IL-4, and IL-13 Superkine molecules exclusively in-licensed from Stanford University. The Superkines are engineered versions of naturally circulating immune system cytokines, designed to enhance cancer-killing properties of immune cells while enabling systemic therapeutic dosing by minimizing their […]
Aptose – Management Conference Call Summary
To kick off the new year in 2024, I requested a conference call with Aptose management to seek answers to numerous questions regarding the company, their clinical program, and primarily the financing that is expected to be completed any day. I had Aptose CEO, Dr. Rice and Fletcher Payne, CFO and CBO on the call. […]
The Relationship between Upfront Payments in a Licensing Deal and Its Success
I am introducing a new series of reports that take a data analytic look at the sector. These use data I collected and coded about various aspects of the sector. If you would like additional information about these data or additional data analysis that can be performed, please contact me at (dsobek@sobekanalytics.com). We know that […]
September 7th Biotech Update
I do not think things are as dire as they may feel in the sector. Obviously, if the broader markets weaken (and this is traditionally a weak month), then the sector will not be able to withstand it. If you squint your eyes just right, we have actually moved higher than the previous lower high […]
August 16th Biotech Update
On a broader market perspective nothing much has changed. We really have no real momentum in either direction but I still think we have a couple of weeks of vacations before people start getting back and volume returns and we get a clearer picture of the sector sentiment or how it is going to developed […]
July 3rd Biotech Update
We at least ended the week well and while there is not a long weekend, we have the day off tomorrow for the 4th of July. I think it is going to be a slow news week and nothing too exciting in the markets. That does not mean that we cannot have a meaningful week, […]
February 15th Biotech Update
It is not the best start so far to the week but it certainly is not bad. We still have the chance to rally and I am a little encouraged by the market reaction to the hotter than expected CPI numbers. It seems to me more signals that inflation and the Fed are losing their […]
Aptose – Path Forward in 2023 With AML “Triplet Therapy”
I had a zoom meeting with Aptose’s CEO and CFO as well, to get updates regarding the new follow-up clinical trials and the timeline in 2023. The CEO was well excited with the move to the new trial in mono & combo with Venetoclax. The 1st mono therapy with 120mg (that has already started) should […]
January 3rd Biotech Update
It is a New Year and two paths diverge in the sector. One would be an unprecedented third year in a row of decline and the second would be the first up year after back to back declines. I am going to use the next couple days to delineate my predictions for 2023. LLY […]
November 15th Biotech Update
We had a nice little continuation yesterday and I would not be surprised if we do not run into a pause that refreshes (or at least it would be healthy to do so). There are a couple of different ways to think about the recent move. I would lean towards the focus on the Fed […]
September 12th Biotech Update
A strong end to last week and it would be ideal for that to continue. The forecast is a little cloudy with some good and bad news out for some big stock. We also have a little lull in the M&A and so I am not sure what impact that has had or will have […]
June 14th Biotech Update
The market is a mess. We had treasuries invert on Friday, which is a favorite signal of an impending recession. To be fair the treasury inversion over predicts recessions and so there have been many instances where nothing happened after an inversion. All that being said rising rates and high inflation is probably bound to […]
December 22nd Biotech Update
It seems to me that the sector is settling into a lull with the markets as we get to Christmas and then New Years. We managed to get out a small rally yesterday and have the chance to do it again today as we start red. While I would like to see more momentum to […]
December 6th Biotech Update
We started lower this morning which is not that bad. I think if we rallied off the start then we likely give it up but a dip to flush out the frustrated traders (and let us be honest that is all of us at this point) might clear the deck for a really rally later […]
BELLUS Health – A Fresh Look at BLU-5937 in Refractory Chronic Cough as A Phase 2b Turnaround Play
We believe this is an opportune time to revisit BELLUS Health (BLU, BLU.TO), as their Phase 2b trial results are set to be released in Q3 (interim analysis) and Q4 (Top-Line results) this year. Recall, this is a clinical stage biopharma company based in Canada (Laval) and the US (Philadelphia), developing novel medicines for the […]
June 8th Biotech Update
So I sort of missed a lot but not really. Obviously I was driving as the biggest binary in recent memory dropped but ASCO was pretty uneventful and the sector is basically still in the same range as when I left. I would hope that the BIIB news will at least get the sector to […]
